Vor Biopharma Inc.
NASDAQ:VORBiotechnology
Healthcare
$17.83 -2.26%
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
52W Low $4.28High $65.80
Volume 0.79M
Average 1.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$142.71M
FY 2025 · Annual
Investing Cash Flow
-$48.80M
FY 2025 · Annual
Financing Cash Flow
$503.81M
FY 2025 · Annual
+843.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Depreciation & Amortization | 1.43M | 2.53M | 3.49M | 3.53M | 2.89M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.32M | 10.7M | 13.36M | 9.85M | 18.91M |
| Change in Working Capital | (9.19M) | (12.69M) | 650K | 5K | 10.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 405K | 0 | 2.85M | 2.24M | 0 |
| Other Working Capital | (9.59M) | (12.69M) | (2.2M) | (2.24M) | 10.21M |
| Other Non-Cash Items | 3.19M | 6.42M | 67K | 3.87M | 521.26M |
| Operating Cash Flow | (69.14M) | (85.14M) | (100.29M) | (99.66M) | (142.71M) |
| Capital Expenditures | (3.89M) | (8.46M) | (1.07M) | (229K) | (941K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (87.76M) | (123.19M) | (74.92M) | (9.91M) | (53.66M) |
| Sales of Investments | 0 | 37.56M | 147M | 107M | 5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 799K |
| Investing Cash Flow | (91.65M) | (94.09M) | 71.01M | 96.86M | (48.8M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 189.2M | 115.98M | 4.58M | 55.83M | 505.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.66M) | 1.17M | (1.64M) | (2.43M) | (1.33M) |
| Financing Cash Flow | 232.91M | 117.14M | 2.94M | 53.39M | 503.81M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 72.12M | (62.1M) | (26.35M) | 50.59M | 312.29M |
| Free Cash Flow | (73.04M) | (93.61M) | (101.36M) | (99.89M) | (143.65M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$696.0M
+ D&A$2.9M
+ Stock-Based Comp$18.9M
+ Deferred Tax$0
+ Working Capital$10.2M
+ Other Non-Cash$521.3M
= Operating Cash Flow-$142.7M
- Capex-$941.0K
= Free Cash Flow-$143.7M
Analysis
FY2025 free cash flow is -$143.7M. FCF conversion is 20.6% of net income. Operating cash flow was -$142.7M, with capex of -$941.0K. The largest bridge item is Other Non-Cash at $521.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 424B5 | 424B5 filing | Oct 30, 2026 | |
| 10-Q | Quarterly report | Oct 30, 2026 |
Does VOR generate free cash flow?
Vor Biopharma Inc. (VOR) generated -$143.65M of free cash flow in fiscal 2025.
How much operating cash flow does VOR produce?
Operating cash flow was -$142.71M, before capital expenditures of $941,000.00.
Continue the stock analysis
Jump to another research area for this company.